Related Experiment Videos
Beta-amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell
P Kerokoski1, H Soininen, T Pirttilä
1Department of Neuroscience and Neurology, University of Kupio, Finland. petri.kerokoski@uku.fi
Neurochemistry International
|January 4, 2001
Summary
Beta-amyloid (Abeta) peptide impairs astrocyte function in Alzheimer's disease by altering vesicular trafficking, not by causing cell death. This disruption may affect crucial supportive roles in the brain.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) involves beta-amyloid (Abeta) peptide deposition, leading to reactive astrogliosis and potential neuronal death.
- Abeta may impair vital astrocyte functions, including glutamate uptake, impacting brain support mechanisms.
Purpose of the Study:
- To investigate the effects of Abeta(1-42) on neonatal rat astrocyte functions.
- To determine if Abeta impacts astrocyte viability, metabolic activity, and proliferation.
Main Methods:
- Primary neonatal rat astrocyte cultures were treated with Abeta(1-42).
- Assays included MTT reduction, cellular ATP content, lactate release, and proliferation.
- Vesicular trafficking was assessed using Bafilomycin A1 and brefeldin A.
Main Results:
- Abeta(1-42) potently decreased MTT reduction without causing cell death, ATP depletion, or altered lactate release.
- Astrocyte proliferation increased upon Abeta(1-42) incubation.
- Abeta(1-42) enhanced MTT dye transfer to the cell surface, mediated by lysosomes, not the Golgi apparatus.
Conclusions:
- Abeta(1-42) does not diminish astrocyte viability but alters their vesicular trafficking.
- Lysosomal pathways are implicated in Abeta-induced changes in astrocyte function.
- Disturbed astrocyte vesicular trafficking by Abeta may compromise their supportive role in Alzheimer's disease.